Citi analyst Joel Beatty maintains a Buy rating on Amarin with a $24 price target following last night's Q4 results. The stock in premarket trading is down 32c to $17.18. The analyst believes Amarin will be successful in its Vascepa patent litigation and sees 20% upside upon the court's decision in March. However, the stock can drop 50% on a negative ruling, Beatty tells investors in a post-earnings research note. In addition, the analyst believes Vascepa sales growth will be strong throughout 2020. The biggest factor impacting Amarin's stock price over the next year is monetizing the European rights to Vascepa, and the implied valuation of the total company from any type of partnership or other transaction that takes place, contends the analyst. He thinks an outright acquisition of Amarin would likely be the best near-term outcome for stockholders. However, if the end of 2020 is reached without some sort of European partnership appearing imminent, it is unlikely the stock price will be much higher at year-end compared to today, contends Beatty.